Lyka Labs inks out-licensing deal with US-based generics firm

The market size of the licensed formulations is about $ 1.4 bn as per IMS March 2017, says Lyka

premium

Lyka Labs

Rakesh Rao Mumbai

Last Updated : May 30 2017 | 12:52 PM IST

Lyka Labs Ltd, a pharmaceutical company that focuses on super specialty segments of injections and dermatology, has entered into an out-licensing & technology transfer deal with an US-based generics company for a basket of 12 sterile injectable formulations for manufacturing, sales and distribution in the US. Lyka has neither disclosed the name of the partnering company nor the financial details of the deal.

The market size of the licensed formulations is approximately $ 1.4 billion as per IMS March 2017. Lyka will be eligible for a royalty on end sales.

“Going forward, Lyka will continue to explore opportunities to monetise its R&D capabilities in the regulated markets through out-licensing partnerships,” said Lyka Labs in a press statement.

Lyka claims to have strong capabilities in sterile preparations and dermatology with its products being marketed across 46 countries globally. From its R&D centre in Mumbai, the company is currently working on development of a wide range of new formulations and new drug delivery system in its focus areas of lyophilisation and dermatology and has a portfolio of over 20 products under development.